Reduced pain associated with 5 activities2
The effectiveness and safety of EUFLEXXA was shown to be comparable to another HA product* in a head-to-head clinical trial. The study was conducted in 321 patients with OA knee pain over a 12-week period.†
- After 3 injections, patients had less pain when climbing stairs, walking, standing, sitting, and rest during the night
- Pain improvement with EUFLEXXA was 62% (P<0.0001) vs 55% with the other product (P<0.0001)‡
In the 12-week study, side effects caused by EUFLEXXA were joint pain (11/160), increase in blood pressure (3/160), joint swelling (3/160), feeling of sickness (3/160), tingling (2/160), back pain (1/160), nausea (1/160), skin irritation (1/160), and tenderness in study knee (1/160).4
*In comparison to Synvisc.
†Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires used by health care professionals to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.5
‡Improvements from baseline were statistically significant for both treatment groups.
Next, find out more about how people have less need for simple pain medications when on EUFLEXXA